Iron deficiency in patients with solid tumours: Prevalence and management in clinical practice

Clinical and Translational Oncology

Volumn 16, Issue 9, 2014, Pages 823-828

  De Castro, J ^a   Gascon P ^b   Casas, A ^c   Munoz Langa J ^d   Alberola, V ^e   Cucala, M ^f   Baron F ^g  

^a HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^e HOSPITAL ARNAU DE VILANOVA   (Spain)

^f Vifor (International) Inc   (Switzerland)

^g HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Anaemia; Cancer; Iron deficiency; Solid tumours

Indexed keywords

ANTINEOPLASTIC AGENT; FERRITIN; HEMOGLOBIN; IRON; TRANSFERRIN;

ADULT; ANEMIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER PATIENT; CANCER STAGING; CLINICAL PRACTICE; DIGESTIVE SYSTEM CANCER; FEMALE; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON THERAPY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; SOLID TUMOR; SPAIN; TRANSFERRIN BLOOD LEVEL; AGED; ANEMIA, IRON-DEFICIENCY; CLINICAL TRIAL; COMPLICATION; MIDDLE AGED; NEOPLASM; PREVALENCE;

AGED; ANEMIA, IRON-DEFICIENCY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PREVALENCE; SPAIN;

EID: 84906938882     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-013-1155-5     Document Type: Article

References (20)

1. Ludwig H, Van BS, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40:2293-306. (Pubitemid 39348881)
2. Cella D, Kallich J, McDermott A, Xu X. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol. 2004;15:979-86. (Pubitemid 39004357)
3. Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist. 2008;13(Suppl 3):33-6.
4. Krayenbuehl PA, Battegay E, Breymann C, Furrer J, Schulthess G. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood. 2011;22(118):3222-7.
5. Aapro M, Osterborg A, Gascon P, Ludwig H, Beguin Y. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol. 2012;23:1954-62.
6. Ludwig H, Muldur E, Endler G, Hubl W. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol. 2013;24:1886-92.
7. Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood. 2010;18(116):4045-59.
8. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;10(352):1011-23.
9. Gascon P, Hermine O, Hoffman C, Aapro M. I.V. iron usage un chemotherapy-induced anaemia: an observational pan-European study. Haematologica. 2012;97(Suppl 1):158.
10. Beale AL, Penney MD, Allison MC. The prevalence of iron deficiency among patients presenting with colorectal cancer. Colorectal Dis. 2005;7:398-402. (Pubitemid 40894871)
11. Beguin Y, Lybaer W, Bosly A. A prospective observational study exploring the impact of iron status on response to darbepoetin alfa in patients with chemotherapy induced anemia. Blood. 2009;114:2007.
12. Kuvibidila SR, Gauthier T, Rayford W. Serum ferritin levels and transferrin saturation in men with prostate cancer. J Natl Med Assoc. 2004;96:641-9. (Pubitemid 38560910)
13. Steinmetz HT, Tsamaloukas A, Schmitz S, Wiegand J, Rohrberg R, Eggert J, et al. A new concept for the differential diagnosis and therapy of anaemia in cancer patients. Support Care Cancer. 2011;19:261-9.
14. Hedenus M, Birgegard G, Nasman P, Ahlberg L, Karlsson T, Lauri B, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia. 2007;21:627-32. (Pubitemid 46444544)
15. Auerbach M, Silberstein PT, Webb RT, Averyanova S, Ciuleanu TE, Shao J, et al. Darbepoetin alfa 300 or 500 mug once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol. 2010;85:655-63.
16. Bastit L, Vandebroek A, Altintas S, Gaede B, Pinter T, Suto TS, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol. 2008;1(26):1611-8.
17. Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist. 2007;12:231-42.
18. Pedrazzoli P, Farris A, Del PS, Del GF, Ferrari D, Bianchessi C, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol. 2008;1(26):1619-25.
19. Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol. 2013;24:475-82.
20. Aapro M. Emerging topics in anaemia and cancer. Ann Oncol. 2012;23(Suppl 10):x289-93.